Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.1800 (2.35%) ($12.1800 - $12.1800) on Fri. Feb. 19, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.03% (three month average) | RSI | 22 | Latest Price | $12.1800(2.35%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -9.6% a day on average for past five trading days. | Weekly Trend | FOLD declines -20.3% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(49%) XBI(49%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -2.515% in a week (0% probabilities). VIXM(-28%) VXX(-13%) UUP(-11%) UNG(-6%) IGOV(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.515% (StdDev 5.03%) | Hourly BBV | 2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-15.84(-230.05%) | Inflection Point | Yes | Resistance Level | $17.65 | 5 Day Moving Average | $12.18(0%) | 10 Day Moving Average | $15.62(-22.02%) | 20 Day Moving Average | $17.65(-30.99%) | To recent high | -51.1% | To recent low | 2.4% | Market Cap | $3.145b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |